Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 14/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 14/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 11/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147011-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS-2 (SARS-COV-2) | VIMU THERAPEUTICS (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220162561-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
| EP-3950060-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | Nissan Chemical Corporation (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-10981927-B2 | Bioactive compounds | THE CAWTHRON INSTITUTE TRUST BOARD (NZ) | 2021-04-20 | — | — | US | disclosed |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020204161-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | 日産化学株式会社 | 2020-10-08 | — | — | WO | disclosed |
| US-20190352309-A1 | BIOACTIVE COMPOUNDS | THE CAWTHRON INSTITUTE TRUST BOARD (NZ) | 2019-11-21 | — | — | US | disclosed |
| US-10364250-B2 | Bioactive compounds | THE CAWTHRON INSTITUTE TRUST BOARD (NZ) | 2019-07-30 | — | — | US | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10040780-B2 | Mcl-1 antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170066747-A1 | MCL-1 ANTAGONISTS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-03-09 | — | — | US | disclosed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040780-B2 | Mcl-1 antagonists | MCL1, BAK1, BCL3 | BCL2L1 4/4885BCL2 9/4885MCL1 1/4885 |
| US-10981927-B2 | Bioactive compounds | BCL9, BCL9L, MALT1 | BCL2L1 47/4885BCL2 49/4885MCL1 10/4885 |
| US-10364250-B2 | Bioactive compounds | CYP8B1, AHR, ALOX12 | BCL2L1 115/4885BCL2 396/4885MCL1 3689/4885 |
| US-20170066747-A1 | MCL-1 ANTAGONISTS | MCL1, BAK1, BCL3 | BCL2L1 4/4885BCL2 9/4885MCL1 1/4885 |
| US-20190352309-A1 | BIOACTIVE COMPOUNDS | BCL9, BCL9L, MALT1 | BCL2L1 47/4885BCL2 49/4885MCL1 10/4885 |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | BCL2L1 20/4885BCL2 11/4885MCL1 233/4885 |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | BET1, BRD2, BRD4 | BCL2L1 83/4885BCL2 121/4885MCL1 93/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885MCL1 8/4885 |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | BCL3, BCL9, BCL2 | BCL2L1 6/4885BCL2 3/4885MCL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.